Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.
Also called NCT01229254
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 189 participants
- Sponsor
- Portola Pharmaceuticals
- Registry
-
NCT01229254
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01229254. Non-randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2017-09-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
- Condition
- Atrial Fibrillation
- Condition
- Atrial Flutter
- Intervention (Drug)
- Amiodarone
- Intervention (Drug)
- Betrixaban 60 mg
- Intervention (Drug)
- Betrixaban 90 mg
- Intervention (Drug)
- Betrixaban 30 mg
- Lead sponsor
- Portola Pharmaceuticals
Record details
- Record id
cardio:ct-nct01229254- Content hash
da3c0356d2c288940c17644914e833a270608bb32250c91b1aaa8d1003756c5b